The MCCC employs both internal and external review mechanisms to inform the strategic decisions made by the Center and to provide feedback necessary for ongoing evaluation of the effectiveness of those decisions. The MCCC's efforts in this regard are broad and encompassing, employing a variety of strategies. Processes are in place for overall strategic planning, review of the established and developing programs, and review of the established and developing shared facilities. They are guided by a clear vision for the Center developed by the Center Director and Senior Leadership and facilitated by Cancer Center Administration. The vision is consistent with the goals of the NCI Centers Program and the mission of the Mayo Clinic, and built upon a careful assessment of the current and future scientific opportunities in cancer research and how the unique capabilities of Mayo Clinic can be leveraged to define areas of particular strength. This overall vision is used to help evaluate recommendations brought forward by leaders of programs and shared facilities - and even individual Center members. These efforts thus inform site and center-wide priorities for portfolio and programmatic stabilization and growth, integration, investment in infrastructure - notably shared resources, recruitment, health disparities and facilities, and use of discretionary resources including CCSG Developmental Funds. The MCCC utilizes expert outside scientists and administrators to provide insight and evaluative expertise in the ongoing review of the Cancer Center. The mainstay of the MCCC's planning and evaluation is the input provided by the External Advisory Committee (EAC). This group, reconstituted and expanded following Dr. Diasio's recruitment in the fall of 2006, has been indispensable in guiding the MCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-37
Application #
8320358
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
37
Fiscal Year
2011
Total Cost
$33,868
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications